The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (MANDARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04157348
Recruitment Status : Active, not recruiting
First Posted : November 8, 2019
Last Update Posted : June 13, 2024
Information provided by (Responsible Party):

Brief Summary:

This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy.

All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period is intended to allow each patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC (earlier enrolled patients may therefore be in the OLE for longer than 1 year).

Condition or disease Intervention/treatment Phase
Eosinophilic Granulomatous Vasculitis Biological: Benralizumab Biological: Mepolizumab Biological: Placebo to Mepolizumab Biological: Placebo to Benralizumab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study)
Actual Study Start Date : October 29, 2019
Actual Primary Completion Date : August 10, 2023
Estimated Study Completion Date : March 31, 2026

Arm Intervention/treatment
Experimental: Benralizumab arm
1x benralizumab SC injection + 3x placebo to mepolizumab SC injections
Biological: Benralizumab
30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)

Biological: Placebo to Mepolizumab
Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)

Active Comparator: Mepolizumab arm
3x mepolizumab SC injections + 1x placebo to benralizumab SC injection
Biological: Mepolizumab
3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)

Biological: Placebo to Benralizumab
Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)

Primary Outcome Measures :
  1. Proportion of patients who are in remission at both weeks 36 and 48 [ Time Frame: week 36 and week 48 ]

    Patients must be in remission at both of these timepoints of weeks 36 and 48.

    Main definition: Remission is defined as BVAS=0 and OCS dose ≤ 4mg/day. Supportive definition: Remission is defined by BVAS =0 and OCS dose ≤ 7.5 mg/day.

    Analysis will be repeated based on main and supportive remission definitions.

Secondary Outcome Measures :
  1. Number of patients in each category of accrued duration of remission [ Time Frame: Up to 52 weeks ]
    The categories of accrued duration of remission are: 0 wk, >0 to <12 wk, 12 to <24 wk, 24 to <36 wk, ≥36 wk. Analysis will be repeated based on main and supportive remission definitions.

  2. Time from randomisation to first EGPA relapse [ Time Frame: During first 52 weeks ]

    Relapse is defined as any of the following:

    • Active vasculitis (BVAS >0); OR
    • Active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR
    • Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions

    warranting any of the following:

    • an increase of OCS therapy (>4mg prednisolone total daily dose or equivalent);
    • an increased dose or addition of an immunosuppressive agent;
    • Hospitalisation related to EGPA worsening.

  3. Based on the average daily prednisolone/prednisone dose during Weeks 48 through 52: [ Time Frame: week 48 through week 52 ]
    • Proportion of patients in each category of average daily prednisolone/prednisone dose during Weeks 48 through 52 using the following categories: 0 mg; > 0 to ≤4 mg; > 4 to ≤ 7.5 mg and > 7.5 mg.
    • Proportion of patients in each category of percent reduction from baseline: no reduction or withdrawal from treatment; < 25% reduction; 25 to < 50% reduction; 50 to < 75% reduction; 75 to < 100% reduction; 100% reduction.
    • Proportion of patients with ≥ 50% reduction from baseline.
    • Proportion of patients with 100% reduction from baseline.
    • Proportion of patients with ≤ 4 mg in average daily dose.

  4. Proportion of patients who have achieved any clinical benefit when meeting any of the criteria below. Proportion of patients who have achieved complete response when meeting all of the criteria below. [ Time Frame: Up to 52 weeks ]
    • Remission (defined as BVAS = 0 and prednisolone/prednisone dose ≤ 4 mg/day) at any time during the double-blind treatment period
    • ≥ 50% reduction in average daily prednisolone/prednisone dose during Weeks 48 through 52
    • EGPA relapse free during the double-blind treatment period. Analysis will be repeated for the supportive remission definition.

  5. Annualized relapse rate [ Time Frame: Over first 52 weeks ]
  6. Proportion of patients who have achieved remission within the first 24 weeks and remained in remission for remainder of the double-blind treatment period [ Time Frame: Up to 52 weeks ]
    Analysis will be repeated based on main and supportive remission definitions.

  7. Change from baseline in VDI [ Time Frame: Up to 52 weeks ]

    Vasculitis Damage Index (VDI)

    Vasculitis Damage Index measures accrued damage across 11 organ systems since diagnosis. Total score is sum of all systems and ranges from 0 to 64 with higher scores indicating more damage.

  8. Change from baseline in BVAS [ Time Frame: Up to 52 weeks ]

    Birmingham Vasculitis Activity Score (BVAS)

    Birmingham Vasculitis Activity Score (BVAS) measures vasculitis disease activity across 9 organ systems. Total score is sum of the weighted organ scores and ranges from 0 to 63 with higher scores indicating higher disease activity.

  9. Change from baseline in pulmonary function [ Time Frame: Up to 52 weeks ]
    As measured by Forced vital capacity (FVC) and Forced Expiratory Volume during first second (FEV1), unit L

  10. Change from baseline in ACQ-6 [ Time Frame: Up to 52 weeks ]

    Asthma Control Questionnaire (6-item version) (ACQ-6 )

    The 6 items in ACQ-6 have a 7-point scale ranging from 0=no impairment to 6=maximum impairment. The ACQ-6 score is calculated by taking the mean of the 6 equally weighted items ranging from 0=well controlled to 6=extremely poorly controlled. Higher scores indicate worse disease control.

  11. Change from baseline in sino-nasal symptoms (SSQ) [ Time Frame: Up to 52 weeks ]

    Sino-nasal Symptoms Questionnaire (SSQ)

    SSQ captures 5 different sino-nasal symptoms over the previous week as scored as none, mild, moderate, severe, or very severe. Higher scores indicate greater severity.

  12. Change from baseline in SNOT-22 [ Time Frame: Up to 52 weeks ]

    Sino-nasal Outcome Test-22 (SNOT-22)

    The 22 items in SNOT-22 have a 6-point scale ranging from 0=no problem to 5=problem as bad as it can be. The total score is the sum of item scores and has a range from 0 to 110. Higher scores indicate poorer outcomes.

  13. Change from baseline in SF-36v2 [ Time Frame: Up to 52 weeks ]

    Short Form 36-item health survey (version 2, acute recall) (SF-36v2)

    The short form 36-item health survey, version 2 (SF-36v2) is a 36-item, self-report survey of functional health and well-being. The assessment yields 8-domain profile consisting of the following: Physical functioning (PF), role limitations due to physical health (RP), bodily pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) are computed from subscale scores to give a broader metric of physical and mental health-related quality of life. The score range is 0 to 100 with higher scores indicating better health status.

  14. Change from baseline in PGIS [ Time Frame: Up to 52 weeks ]

    Patient Global Impression of Severity (PGIS)

    PGIS is a 6-point categorical response scale ranging from 0=no symptoms to 6= very severe symptoms. Higher scores indicate worse severity.

  15. Change from baseline in WPAI [ Time Frame: Up to 52 weeks ]

    Work productivity and Activity Impairment Questionnaire (WPAI)

    WPAI consists of 6 questions regarding absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment. WPAI outcomes are scored as impairment percentages, with a higher percentage indicating greater impairment and less productivity.

  16. Change from baseline in blood eosinophil counts [ Time Frame: Up to 52 weeks ]
  17. Proportion of PGIC responders at each weekly assessment [ Time Frame: Up to 4 weeks ]

    Patient Global Impression of Change (PGIC)

    Patient Global Impression of Change (PGIC) measures the patient´s overall impression of response to treatment since the initial dose using a 7-point scale ranging from "much better", "about the same" to "much worse". Lower scores indicate better health status.

Other Outcome Measures:
  1. Numbers of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Minimum of 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects age 18 years or older.
  2. EGPA diagnosis based on history or presence asthma and eosinophilia (>1.0x10^9/L and/or >10% of leucocytes) and at least 2 of; biopsy with eosinophilic vasculitis or perivascular/granulomatous inflammation; mono-or polyneuropathy, non-fixed pulmonary infiltrates, sino-nasal abnormality; cardiomyopathy; glomerulonephritis; alveolar haemorrhage; palpable purpura; anti neutrophil cytoplasmic anti-body (ANCA) positivity (Myeloperoxidase or proteinease 3).
  3. History of relapsing (at least 1 confirmed EGPA relapse within last 2 years and > 12 weeks prior to screening), or refractory (failure to attain remission, defined as BVAS=0 and oral corticosteroid (OCS) dose <=7.5 mg/day of prednisolone or equivalent, following standard induction regimen for at least 3 months and within 6 months prior to screening, or recurrence of symptoms upon OCS tapering at any dose of ≥7.5 mg/day prednisolone or equivalent.

    If induction with glucocorticoidsalone, patient must have failed to attain remission after 3 months and the glucocorticoid dose must be ≥15 mg/day prednisolone or equivalent for the 4 weeks prior to randomization.

  4. Must be on a stable dose of oral prednisolone or prednisone of ≥7.5 mg/day (but not >50mg/day) for at least 4 weeks prior to randomization.
  5. If receiving immunosuppressive therapy (excluding cyclophosphamide) the dose must be stable for the 4 weeks prior to randomization and during the study (dose reductions for safety reasons will be permitted).
  6. QTc(F)<450 msec or QTc(F)<480 msec for patients with bundle branch block.
  7. Females of childbearing potential must use an acceptable method of birth control from randomization for at least 12 weeks after the last study drug administration.

Exclusion Criteria:

  1. Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
  2. Organ or life-threatening EGPA < 3 months prior to screening
  3. Currently pregnant or breastfeeding, or planning to become pregnant during study participation.
  4. Current malignancy or history of malignancy, unless received curative therapy >5 years ago, or >1 year ago for basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix
  5. An untreated or refractory helminth parasitic infection < 24 weeks prior to screening
  6. Unstable liver disease
  7. Severe or clinically significant, uncontrolled cardiovascular disease
  8. Other concurrent disease that may put the patient at risk, or may influence the results of the study, or the patients' ability to complete entire duration of the study
  9. Chronic or ongoing infectious disease requiring systemic anti-infective treatment
  10. Known immunodeficiency disorder or positive HIV test
  11. Prior receipt of mepolizumab, reslizumab, dupilumab or benralizumab. Receipt of intravenous/intramuscular/subcutaneous corticosteroids within 4 weeks prior to randomization, receipt of omalizumab within 130 days prior to screening, rituximab within 6 months prior to screening (or B-cells not recovered), interferon-α or alemtuzumab within 6 months prior to screening, receipt of anti-tumor necrosis factor therapy within 12 weeks prior to screening or an investigational non-biologic product within 30 days or 5 half-lives prior to screening, whichever is longer. Receipt of any other marketed or investigational biologic products within 4 months or 5 half-lives prior to screening, whichever is longer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04157348

Show Show 50 study locations
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Michael Wechsler, MD National Jewish Health, 1400 Jackson St Denver, CO 80206
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT04157348    
Other Study ID Numbers: D3253C00001
2023-510248-19-00 ( Other Identifier: EU Trial (CTIS) Number )
2019-001832-77 ( EudraCT Number )
First Posted: November 8, 2019    Key Record Dates
Last Update Posted: June 13, 2024
Last Verified: June 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal All requests will be evaluated as per the AZ disclosure commitment:

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at
Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
Inhaled corticosteroids
Eosinophilic Granulomatous Vasculitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Churg-Strauss Syndrome
Vascular Diseases
Cardiovascular Diseases
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Systemic Vasculitis
Lymphoproliferative Disorders
Lymphatic Diseases
Skin Diseases, Vascular
Skin Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Asthmatic Agents
Respiratory System Agents